Welcome!

News Feed Item

European Researchers Invited to Submit Study Proposals for Bristol-Myers Squibb's Partnering for Cure™ Virology Research Programme

PARIS, April 8, 2014 /PRNewswire/ --

Partnering for Cure is Bristol-Myers Squibb's flagship, Pan-European scientific initiative supporting breakthrough research and facilitating greater collaboration and knowledge-sharing with the virology community 

In advance of this year's International Liver CongressTM 2014 in London, England, Bristol-Myers Squibb invites European researchers to submit innovative research ideas that aim to cure chronic virological diseases. As part of Bristol-Myers Squibb's ongoing commitment in virology, these projects provide an opportunity for researchers, particularly junior faculty and young investigators, to accelerate novel solutions that could lead to cures in HIV, hepatitis B (HBV) and hepatitis C (HCV).

This latest round of research applications will be accepted from 1 May to 15 July 2014 and aspiring scientists are encouraged to submit their ideas at http://www.bms.com/israpplications. Priority will be given to research proposals in the area of translational science with a clear relevance for the clinical development of a cure in viral hepatitis or HIV infection.

Partnering for Cure is led by the Partnering for CureFaculty, an expert panel of clinical and research experts from across Europe and focuses on three pillars - education, scientific exchange and scientific research. The Faculty will award up to four recipients in a blinded evaluation after applications close. The four research applicants will share between them just over €300,000 in support from Bristol-Myers Squibb.

"This year, we were proud to announce our first class of Partnering for Cureresearch programme recipients in January," said Professor Jürgen Rockstroh, Partnering for Cure Faculty Chair. "Now we're looking for even more proposals to expand our clinical network and continuing the fight against chronic viral diseases through the 2014 Partnering for Cure research programme."  

Matthieu Perreau, Centre Hospitalier Universitaire Vaudois (CHUV) Service Immunologie et Allergie, Switzerland, was one of the four Partnering for Cure research programme recipients last year, awarded for his research, Identification of the memory CD4 T-cell population(s) harbouring replication competent HIV-1 within lymphoid tissues.

"This grant has provided me with the opportunity to pursue my passion and make an impact in the virology community," remarks Perreau. "It is an honour to be part of this exciting initiative, and I look forward to working with my research colleagues to find a cure."

"Bristol-Myers Squibb has a longstanding vision of continuing to transform the treatment of viral diseases and fulfilling serious unmet medical needs of patients," said George Hanna, MD, vice president, HIV Development, Bristol-Myers Squibb. "We look forward to this year's applications and supporting the upcoming generation of researchers and scientists who are dedicated to improving treatments and delivering true advances in patient care."

The projects that will receive support from Bristol-Myers Squibb will be announced on World AIDS Day - 1 December 2014.

About Partnering for Cure 

Partnering for Cure is a European medical education programme developed as part of Bristol-Myers Squibb's ongoing commitment to virology research, education and transforming clinical outcomes for patients with chronic viral diseases. The programme focuses on recent and ongoing cure research in HIV, HBV and HCV.

The objectives of the programme are to:

  • Provide medical education to physicians interested in virology cure research
  • Provide support to researchers active in virology cure research
  • Provide a forum for physicians and researchers to discuss advances in virology cure

The Partnering for Cure initiative reinforces Bristol-Myers Squibb's commitment in virology, which is rooted in the company's legacy in virology and ongoing research in HIV and viral hepatitis. Chronic viral infections make a substantial contribution to the burden of chronic diseases and premature mortality worldwide. In December 2012, the Global Burden of Disease Study reported 1,465,000 deaths caused by HIV/AIDS and 1,445,000 deaths caused by viral hepatitis in 2010.[i] Infections with hepatitis B and C viruses also cause an estimated 57 percent of cases of liver cirrhosis and 78 percent of cases of primary liver cancer annually.[ii] Whilst important advances have been made over the last decade significant unmet needs and the opportunity for cure remains, particularly in HIV.

Bristol-Myers Squibb's Commitment to Virology 

For over 20 years, Bristol-Myers Squibb has worked collaboratively with the virology community to help meet the needs of patients living with HIV, HBV and HCV - by providing and developing medicines such as Zerit®, Videx®, Sustiva®, Atripla[®*], Reyataz®, Baraclude®, supporting clinical research on new innovative compounds, supporting disease education efforts, and improving access to medicines in the developing world.

Bristol-Myers Squibb supports a number of scientific and educational programs within the virology community around the world that encompass disease education, disease awareness and sharing of best practices. In addition to Partnering for Cure these include SHE® (Strong, HIV positive, Empowered Women/Strong, HIV positive Women Educational Programme), a comprehensive and innovative programme for women living with HIV and their healthcare providers, PATH B® (Patients and professionals acting together for hepatitis B), a joint initiative between hepatitis patient groups and hepatologists to provide comprehensive information and support for patients with chronic hepatitis B.

Additionally, Bristol-Myers Squibb Foundation's philanthropic and educational programmes, such as Secure the Future® and Delivering Hope® aim to support people living with HIV in Africa and with viral hepatitis in Asia, through numerous private-public partnerships and community based projects.

VIRUK14NP01991-01

Prepared April 2014

* Atripla® is a trademark of Bristol-Myers Squibb Co. and Gilead Sciences, Inc.

i. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, The Lancet, Volume 380, No9859, Dec 15, 2012 pp2095-2128

ii. WHO and WHA, Global Policy Report on the Prevention and Control of Viral Hepatitis, 2013, http://global-report.worldhepatitisalliance.org/en/home.html


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, showed how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningful f...
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
"Once customers get a year into their IoT deployments, they start to realize that they may have been shortsighted in the ways they built out their deployment and the key thing I see a lot of people looking at is - how can I take equipment data, pull it back in an IoT solution and show it in a dashboard," stated Dave McCarthy, Director of Products at Bsquare Corporation, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
IoT is rapidly changing the way enterprises are using data to improve business decision-making. In order to derive business value, organizations must unlock insights from the data gathered and then act on these. In their session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, and Peter Shashkin, Head of Development Department at EastBanc Technologies, discussed how one organization leveraged IoT, cloud technology and data analysis to improve customer experiences and effici...
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
The cloud competition for database hosts is fierce. How do you evaluate a cloud provider for your database platform? In his session at 18th Cloud Expo, Chris Presley, a Solutions Architect at Pythian, gave users a checklist of considerations when choosing a provider. Chris Presley is a Solutions Architect at Pythian. He loves order – making him a premier Microsoft SQL Server expert. Not only has he programmed and administered SQL Server, but he has also shared his expertise and passion with b...
"IoT is going to be a huge industry with a lot of value for end users, for industries, for consumers, for manufacturers. How can we use cloud to effectively manage IoT applications," stated Ian Khan, Innovation & Marketing Manager at Solgeniakhela, in this SYS-CON.tv interview at @ThingsExpo, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...